Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.ents. Correlates with Alzheimer disease

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.ents. Correlates with Alzheimer disease

Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market. The usefulness of these antagonists has been deduced from studies demonstrating functi...

Full description

Bibliographic Details
Main Authors: Armentero, M.T. (Marie Therese), Pinna, A. (Annalisa), Ferre, S. (Sergi), Lanciego, J.L. (José Luis), Müller, C.E. (Christa E.), Franco, R. (Rafael)
Format: info:eu-repo/semantics/article
Language:eng
Published: Pergamon Elsevier Science LTD 2012
Subjects:
Basal ganglia
Receptor heteromer
Heteromer-selective antagonist
Neuroprotection
Postsynaptic heteromer
Presynaptic heteromer
Online Access:https://hdl.handle.net/10171/22827

Similar Items

Similar Items